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Objectives: To estimate hospital costs for cardiovascular (CV) events and revas-
cularisation procedure associated with inpatient care analysing data from 14 
acute care Spanish hospitals (RECH network), and to compare these costs with 
national tariffs for the corresponding diagnosis-related groups (DRGs) for similar 
events. MethOds: A retrospective study (period: 2009-2013) collecting data from 
discharge records (~1,050,000) from adult patients was performed. Mean costs and 
length of stay per patient were collected for non-fatal events according primary 
diagnosis (CIE9-MC) including myocardial infarction (MI), unstable angina, conges-
tive heart failure (CHF) with hospitalization, stroke, revascularisation procedures 
and CV death. Average costs per patient for non-fatal CV events, revascularisa-
tion procedures and CV death were estimated according per-patient cost informa-
tion from the RECH database, that included both AP-DRG and APR-DRG groupers 
which are used for alternative cost comparisons. Subsequently, observed costs per 
DRG were compared with national DRG tariffs. All costs were expressed in € for 
the year 2014. Results: Mean costs based on patient-level data from the RECH 
network for non-fatal acute MI, unstable angina, CHF with hospitalisation, stroke 
and revascularisation procedures were € 8,669, € 3,162, € 3,353, € 4,644 and € 10,159 
respectively. Average length of stay for non-fatal events ranged between 5.3 and 
10.2 hospitalisation days and between 6.4 and 19.5 for revascularisation proce-
dures. The comparison of costs from the RECH network with national tariffs for 
AP-DRGs, showed differences of € 57 for revascularisation procedures, € 298 for CHF 
with hospitalisation, € 1,096 for unstable angina, € 1,316 for stroke, € 3,794 for CV 
death and € 4,249 for acute MI. cOnclusiOns: Average per-patient costs based 
on discharge records from the RECH network for CV events and revascularisation 
procedures were higher than the national tariffs for AP-DRGs of similar events and 
procedures. These differences may result in important economic consequences for 
the Spanish health system.
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urban emPloyee basiC mediCal insuranCe
Xie X
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Objectives: To understand the hospitalization expenses and the cost-sharing situ-
ation among Chinese stroke patients covered by Urban Employee Basic Medical 
Insurance (UEBMI). MethOds: The data are derived from China Health Insurance 
Research Association’s (CHIRA) Survey (2012). The survey adopts the systematic 
sampling method to draw samples from the inpatients with UEBMI of the previous 
year and gets details about their disease diagnosis, medical service utilization and 
expenses. The sampling rate varies with different regions with an average rate of 
2%~10%. SPSS17.0 is used to conduct the statistical analysis. Results: A total of 
22,765 stroke patients were obtained from the sampling. The proportion of male 
stroke patients (59%) was obviously higher than female patients (41%). As for age, 
stroke patients aged 70~79 accounted for the highest ratio (32%), followed by 60~69 
(27%) and 50~59 (19%). The average LOS of stroke patients was 16.2 days, which 
was longer in the tier-3 hospitals (17.4 days) than in the tier-2 ones (15.3 days). The 
average hospitalization expenses were 8,598 yuan, the average drug expenses were 
5,049 yuan, accounting for about 59% of the total hospitalization expenses. Average 
costs of the tier-3 hospitals were higher than other hospitals, with the average hos-
pitalization expenses being 13,381 yuan and the average drug expenses being 7,318 
yuan (occupying about 55% of the hospitalization expenses). The UEBMI payment 
accounted for about 69% of the total hospitalization expenses and about 79% of the 
drug cost. Patients’ co-payment proportion was higher in tier-3 hospitals than other 
ones. cOnclusiOns: Chinese stroke patients are mostly over 50 years old, with 
more male patients than female patients. The average hospitalization expenses 
are 8,598 yuan and payer’s payment proportion is lower than 70%. Expenses of the 
tier-3 hospitals are apparently higher than other hospitals. Medicine charges take 
up more than half of the hospitalization expenses.
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Objectives: Comparative evaluation of the cost effectiveness of treatment of 
patients with acute coronary syndrome without ST segment elevation (ACS) effi-
ciency using two therapy schemes in Ukraine. MethOds: “The cost-efficiency” 
method was used to carrying out the study. Analysis was based on the results of 
opened international multicenter randomized trial of efficiency of tiazotic acid 
morpholinium salt in ACS patients. The clinical trial involved 100 patients rand-
omized into main and control groups (each group contained 50 patients). Standard 
therapy (narcotic analgesics, seduction drugs, nitrates, β -blockers, anticoagulants, 
antithrombotic drugs, calcium channel blockers, ACEs, sartans and statins) and 
injections of tiazotic acid morpholinium salt were administrated in the main group; 
only standard therapy was administrated in the control group. Treatment of patients 
was carried out during 14 days. For determining the cost of a course therapy for 
a patient with craniocerebral injury only the direct costs in the studied regimens 
were taken into account. Drugs prices were taken from Morion’s information system 
(May, 2015). As an indicator of the effectiveness after treatment were considered the 
following: 5 % increase in ejection fraction, 10 % decreasing in myocardial ischemia 
duration (based on Holter ECG monitoring), 10 % decrease in quantity of ventricu-
lar arrhythmia episodes (based on ECG Holter monitoring). Results: The treat-
ment efficiency in main group patients was 84 % and 54 % in controls. Treatment 
during 2012, 2013 and 2014. Two health regions of Spain (Comunitat Valenciana with 
4.949.219 inhabitants and Extremadurawith 1.093.587. Total population: 6,042,806) 
where compared. In order to make it comparable, DDDs where measured as num-
bers of DDDs/1000 inhabitants/day (DHDs). Results: Atorvastatin and simvastatin 
are the most prescribed statins in both regions. However in Extremadura, the pro-
portion of DHD of these two chemical substances over the total amount of statins 
has decreased from 70.13% in 2012 to 68.00% in 2014. By contrast, in Comunitat 
Valenciana the proportion has increased from 73.45% in 2012 to 82.40% in 2014. In 
both regions the number of DHD of statins increases (in Extremadura from 106.75 
DHD in 2012 to 120.14 DHD in 2014; in Comunitat Valenciana from 98.08 DHD in 
2012 to 104.15 DHD in 2014). However, in Comunitat Valenciana the increase in 
consumption has not resulted in increased drug spending but in a drop of 7.41%. 
By contrast, Extremadura’s pharmaceutical expenditure of statins has increased 
a 17.62%. cOnclusiOns: In the region that did not introduced the algorithm for 
statins into the electronic prescribing tool, less cost effective statins are gaining 
market share. In the region which introduced the prescription algorithm, although 
statin use increases, its pharmaceutical expenditure decreases, resulting in savings 
that can be spent elsewhere medication.
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Objectives: The Prescription e-Protocols for Medicines (PePM), which devel-
oped under the coordination of the Athens Medical Society (AMS), are to be used 
by all physicians as an aid in prescription and to set out a framework of “good 
medical practice”, based on the up-to-day clinical evidence. To make the use of 
prescription protocols efficient, the main objective was to transform the proto-
col’s information into machine processable format, integrate with the national 
e-prescription system and measure the cost impact. MethOds: AMS has already 
developed prescription e-protocols for seven therapeutic categories (20 proto-
cols). The representation model of PePM includes five levels of information: gen-
eral information, treatment steps and sub-conditions according the use of risk 
assessment algorithms, treatment at active substance level and at product level. 
The process of prescribing according to PePM, includes: select protocol accord-
ing to ICD10 diagnoses, insert input parameters, select medication and finalize 
prescription. Their cost impact was measured by comparing the periods of using 
the protocols with the relevant period not using them on the Greek National 
ePrescription system. Results: Using the example of the dyslipidemia proto-
col and the stratification of the population according to heart score algorithm, 
comparing statins use, between two periods (09-11/2013 vs 09-11/2014) had an 
overall reduction of the cost by 15.85%. Reduction of the second step statins’ 
cost: atorvastatin -17.16%, rosuvastatin -3.93%, ezetimibe -29.83%, ezetimibe/
simvastatin -12.38%. cOnclusiOns: The recent economic crisis and subse-
quent public expenditure cuts have slowed the rate of heath expenditure growth. 
Pharmaceutical expenditure has even decreased as it has been identified as one 
of the main areas of public spending cuts. Our proposal concerns that suitable 
prescribing guidelines with the integration on the ePrescription system ensures 
patient access to quality health service and containing costs according to real 
health needs and in alignment with evidence-based medicine principles.
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Objectives: To estimate monthly medical costs of controlled and inadequately-
controlled non-valvular atrial fibrillation (NVAF) patients treated with Vitamin K 
antagonists (VKA). MethOds: Retrospective cohort study of NVAF patients newly 
initiating VKA between January 2009 and December 2014 using a database from 
a healthcare provider from Badalona (Spain) (120,000 inhabitants). We followed 
patients from first VKA treatment until study end, leaving database, VKA discontin-
uation, or death; calculated proportion of patients with adequate anticoagulation 
(time in therapeutic range (TTR) ≥ 60% using target international normalized ratio 
(INR) 2-3) over 12 months post-initiation; and estimated monthly mean healthcare 
costs linked to NVAF for controlled and inadequately-controlled patients, adopting 
a payer perspective. Results: The study included 1,144 patients (median(IQR) 
follow-up 28.8 (14.2–43.1) months) with 67.1% well-controlled patients over 0-12 
month period. At baseline, for controlled and inadequately-controlled patients 
respectively, mean(SD) age was 74.3(10.3) and 74.3(10.7) years and 48.2% and 
54.3% were female. Mean Charlson index was 0.9(1.4) and 1.1(1.4), (p:0.025), and 
CHA2DS2-VASc scores were 2.7(1.6) and 2.9(1.6) (p:0.038) for controlled and inad-
equately-controlled patients, respectively. Mean(SD) monthly medical costs were 
€ 80.3(174.8) and € 143.6(656.6) respectively, being 1.8-fold higher for inadequately-
controlled patients (p:0.013). The largest cost components were general practi-
tioner visits, hospitalizations, and specialist visits. INR testing was also more 
costly in inadequately-controlled patients (mean monthly INR cost(SD) € 2.3(1.1) 
versus € 2.7(1. 9) p:< 0.001 for controlled and inadequately-controlled patients 
respectively) and accounted for 1.9% and 2.9% of costs, respectively. Other time 
periods assessed gave qualitatively similar results. cOnclusiOns: In this study, 
1/3 of NVAF patients treated with VKAs were inadequately controlled. These 
patients had a higher baseline stroke risk and comorbidity index and generated 
higher direct medical costs associated with NVAF compared to controlled patients. 
In this context, future research could address the medical costs associated with 
novel anticoagulants in NVAF patients.
A386  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
CHA2DS2-VASc and HAS-BLED clinical risk score. Results: Totally, 10,099 patients 
fulfilled our study criterions. The total annualized direct cost of NVAF patient was 
1,627.9 euro ±1,076.6. The main cost component was the hospitalization (68.0%), 
followed by drug use (24.6%) and outpatient services (7.4%). The predictors of the 
total cost were male (RR: 1.37, CI: 1.29-1.45 versus female), incident (RR: 4.60, CI: 4.30-
4.92 versus prevalent patient), switcher (RR: 1.88, CI: 1.72-2.06 versus no switcher), 
CHA2DS2-VASc score (RR: 6.34, CI:5.08-7.92 for score 7 versus score 0) and HAS-BLED 
(RR: 1.36, CI:1.25-1.48 for score > 3 versus score ≤ 3). cOnclusiOns: NVAF places an 
enormous burden on health care system. Hospitalization as major cost driver high-
lights the potential cost-effectiveness of disease management targeted at reducing 
risks of serious cerebrovascular events among NVAF patients.
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Objectives: The innovative technologies for aortic stenosis (AS) treatment 
require in-depth analysis of the costs associated with disease and comorbidi-
ties. To quantify health care resources consumed by AS patients’ treatment 
(drugs, diagnostic tests, hospital outpatient and inpatient) and estimate the 
total direct costs. MethOds: We conducted a retrospective observational 
cohort analysis using data from administrative databases of Local Health 
Authority of Milan in Italy. The study population included all subjects hospi-
talized with principal or secondary AS diagnosis between January 1, 2007 and 
December 31, 2011 (enrollment period). All subjects were observed for two 
years after the first hospitalization (index hospitalization). Patient characteri-
zation was related to the two years before index hospitalization (characteri-
zation period). Data related to hospitalizations, drugs and hospital outpatient 
during both periods were collected for each patient to quantify the resources 
consumption. The hospitalization costs were estimated using DRG tariffs and 
hospital outpatient costs with regional tariffs. The drugs consumption was evalu-
ated through the tear-off tab prices. Results: 919 patients were included (mean 
age 71.3 ± 11.6; 51% males). The mean cost of illness per patient is € 16,271 and € 
13,916, in the characterization and observation period respectively. Of all treated 
patients, 323 (35 %) underwent surgical procedure. The mean cost of illness for 
these patients is € 28,365 and € 8,002, in the characterization and observation 
period respectively. Considering only costs related to cardiovascular disease, the 
mean cost per patient is € 3,470 and € 2,272 in the characterization and obser-
vation period respectively. cOnclusiOns: The cost of illness in AS patients is 
lower in the period after admission, especially when patients underwent cardiac 
valve treatment.
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Objectives: Hyperkalemia is a metabolic abnormality seen frequently in the 
Emergency Department. The most common condition leading to hyperkalemia is 
missed dialysis in a patient with end stage renal disease (ESRD), but many other 
conditions can predispose an individual to hyperkalemia, such as acute renal fail-
ure, extensive burns, trauma, or severe rhabdomyolysis or severe acidosis. The 
objective of this study was to assess the resource burden on United States emer-
gency room departments due to hyperkalemia. MethOds: The number of emer-
gency room (ED/ ER) visits due to hyperkalemia, with International Classification 
of Diseases (ICD-9) code 276.7, were estimated using the Centers for Medicare & 
Medicaid Services (CMS) Agency for Healthcare Research and Quality (AHRQ) 2011 
data for ED visits. A review of recent publications on hyperkalemia management 
was also conducted using the databases Pubmed, Embase, Biosis, Google Scholar 
and Cochrane. Results: The annual number of ED visits with Hyperkalemia as 
one of the diagnoses is estimated to be 814,181 (SE 23,526). The annual number of 
ED visits with Hyperkalemia as the first listed diagnosis is estimated to be 66,989 
(SE 2284. Among the age groups 18-44, 45-64, 65-84, 85+ the majority of ED visits 
were in the 45-64 (36.04%) and 65-84 (39.44%) groups (hyperkalemia as the first 
listed diagnosis). Among the five payer types, Medicare, Medicaid, Private insurance, 
Uninsured and Other, the majority of patients belonged to Medicare (68.41%). The 
trend was similar for patients with Hyperkalemia as one of the diagnosis or first 
diagnosis. cOnclusiOns: This analysis confirms previous findings that hyper-
kalemia is common in the emergency department. There is a need for quick, safe 
and effective treatments for hyperkalemia, which can be easily administered in 
emergency department setting.
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Objectives: The high prevalence of obesity and overweight leads to frequent use 
of health care resources. Studies aimed at assessment of damages caused by this 
medico-social problem are seen as very important at last years. The main aim of this 
study was to assess burden of obesity and overweight in Russia taking as an example 
three main social diseases: stroke, heart attack, and diabetes mellitus. MethOds: 
Available evidence on assessment of costs of management and treatment of obese 
and overweight patients and its relation to the disorders selected were analyzed. 
To measure costs of obesity and overweight for the state budget were used “cost 
of illness” analysis with consideration of risks of stroke, heart attack, and diabetes 
mellitus in the population (G. Oster et al, 2000). Taking into account specific fea-
tures of cost assessment and based on publically available data were developed 
costs were € 56,77 and € 39,18 correspondingly. “The cost-efficiency” analysis 
demonstrated that CER in main group was € 67,58 and CER in control group was € 
72,56. cOnclusiOns: The “cost-efficiency” analysis demonstrated that adminis-
tration of tiazotic acid morpholinium salt in combination with standard therapy 
is more effective and less expensive in ACS patients. The obtained results allow to 
optimize treatment expenditures for a state, insurance companies and patients.
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Objectives: About two-thirds of stroke survivors develop post-stroke sequelae, 
including spasticity. The burden of post-stroke spasticity (PSS) is high in terms of 
treatment costs and the effects of comorbidities. Our objective was to describe the 
burden of PSS in terms of healthcare resource utilization and costs, and quantify 
the difference between patients who develop PSS and those who do not. MethOds: 
This retrospective study used the THIN database. Adult patients with a stroke 
between 1Jan2007 and 31Dec2012 were included. PSS diagnoses were found to be 
under-represented; machine learning methodology was applied to identify poten-
tially undiagnosed PSS. Cases were defined as patients with diagnosed or predicted 
PSS in the 12 months after stroke; for patients without PSS, each stroke acted as 
a control event. PSS cases were matched to controls on age, gender, prior strokes, 
socioeconomic status, and comorbidities, using the nearest neighbour algorithm. 
Direct healthcare resources, including primary care visits, all-cause hospitalisations, 
and specialist referrals during the year post-stroke, were costed out at 2014 GBP 
rates, using public sources. Results: Of the 3,082 PSS cases and 28,753 controls, 
56% were female and 49% were 75 years or older. During the first year, 33% of the 
PSS cases were hospitalised, compared to 9% of the controls. Specialist referrals 
were recorded for 76% of PSS patients and 64% of controls. Primary care utilisation 
was similar for both groups. Total average costs per patient were £1,270 (SD: 772) 
for cases and £631 (SD: 496) for controls. After adjusting for other covariates, a sig-
nificant increase in cost for the PSS patients was found; on average £635 in the 12 
months post-stroke. cOnclusiOns: The costs for patients who develop PSS after 
stroke are twice as high as those for patients who do not develop spasticity, with 
the major driver being the number of hospitalisations.
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Objectives: Estimate the incremental annual cost after a myocardial infarction 
(MI) MethOds: A French representative cohort of patients who had a MI in France 
between 2007 and 2011 was extracted from a claim database of 600,000 patients. 
Costs were calculated from a community perspective, restricted to direct costs and 
from a health insurance scheme perspective. This analysis was performed on sub-
jects still alive one year after MI Results: A total of 1,920 subjects were identified 
with an index MI: 2/3 were males, mean age= 67.2 y, 20.6% had diabetes, 37.6% 
hypercholesterolemia and 82.4% hypertension. Among the 1,920 subjects, 346 died in 
the first year and 3 were lost to follow-up: the cost was performed on 1,571 patients. 
The annual cost from a health insurance scheme perspective approximately tripled 
as it increased from € 3,940 to € 11,914 after a MI: Hospital cost increased from € 1,616 
before the index MI to € 6,470 after hospitalization (the cost of the index hospitaliza-
tion is excluded from the cost); Average community-based care costs increased from 
€ 2,323 before the index MI to € 5,443 after: Travel costs increased from 127€ to 573€ ; 
Fees related to physician consultations increased from 589€ to 1,676€ (annual mean 
number consultations with a general practitioner and a specialist increased from 
7.6 to 10.9 and from 5.4 to 10 respectively); Fees related to laboratory tests increased 
from 139€ to 408€ ; Cost of medicinal products increased from 1,105€ to 2,283€ ; Cost 
of medical non physician health professionals increased from 380€ to 534€ . It should 
be noted that the mean cost related to the index MI hospitalization was € 5,876 . The 
evolution of the costs from a community perspective was similar. cOnclusiOns: 
The economic impact of recurrent cardiovascular events is substantial since health-
care consumption costs almost tripled after the index MI event
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Objectives: To determine the direct healthcare costs associated with non-valvular 
atrial fibrillation (NVAF). MethOds: A population-based cohort study was con-
ducted using administrative data from a local health authority in the Campania 
Region (~1,000,000 inhabitants). NVAF was defined as one or more claims for atrial 
fibrillation (ICD-9-CM code 427.31) between January 1, 2005 and June 30, 2014, where 
none of the claims was associated with cardioversion or cardiac ablation and there 
was no evidence of valve-related diagnoses or procedures. All patients were fol-
lowed from June 30, 2014 until death or end of study follow-up (December 31, 2014). 
The direct costs were reported as average annualized cost (per patient per month 
multiplied by 12). Costs were divided into hospitalizations, outpatient services and 
pharmacy claims. Generalised linear mixed models under gamma distribution were 
used to identify predictors of cumulative healthcare costs. Rate Ratios (RRs) and 95% 
confidence intervals (CIs) were adjusted for age, gender, incident patients, switcher, 
